Clinical Trial Update: Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and efficacy of Technosphere Insulin Inhalation Powder with Lantus, compared to Humalog and Lantus, over 16 weeks in type 1 …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)
• Humalog (insulin lispro)
• Lantus (insulin glargine)

Snippet

Sponsor: Mannkind Corporation | Conditions: Diabetes, Type 1 | Phase 3 | Status: TERMINATED | Results posted: 2014-10-16